[1]章玲艳,吴会晨,汪 飞,等.参苓白术散加减对结直肠癌患者化疗后骨髓抑制和免疫功能的影响[J].陕西中医,2023,(8):1086-1089.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.020]
　ZHANG Lingyan,WU Huichen,WANG Fei,et al.Effects of modified Shenling Baizhu powder on bone marrow suppression and immune function in patients with colorectal cancer after chemotherapy[J].,2023,(8):1086-1089.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.020]
点击复制

参苓白术散加减对结直肠癌患者化疗后骨髓抑制和免疫功能的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年8期
页码:
1086-1089
栏目:
临床研究
出版日期:
2023-08-05

文章信息/Info

Title:
Effects of modified Shenling Baizhu powder on bone marrow suppression and immune function in patients with colorectal cancer after chemotherapy
作者:
章玲艳; 吴会晨; 汪 飞; 朱电波
(铜陵市人民医院,安徽 铜陵 244000)
Author(s):
ZHANG Lingyan; WU Huichen; WANG Fei; ZHU Dianbo
(Tongling People's Hospital,Tongling 244000,China)
关键词:
结直肠癌;  参苓白术散;  肿瘤标志物;  免疫功能;  骨髓抑制;  生活质量
Keywords:
Colorectal cancer;  Shenling Baizhu powder;  Tumor markers;  Immune function;  Bone marrow suppression;  Quality of life
分类号:
R 735.3
DOI:
DOI:10.3969/j.issn.1000-7369.2023.08.020
文献标志码:
A
摘要:
目的:探讨参苓白术散加减对结直肠癌(CRC)患者化疗后骨髓抑制及对免疫功能的影响。方法:选择行化疗的61例CRC患者,根据随机数字表法分为对照组和中药组。对照组31例,接受XELOX、FOLFOX或SOX化疗方案治疗; 中药组30例,在对照组的基础上接受参苓白术散加减治疗,两组均连续治疗2个周期。对比两组中医症候积分、肿瘤标志物、血常规、卡氏功能状态评分(KPS)、结直肠癌生活质量专用量表(QLQ-CR38)评分、不良反应及临床疗效。结果:治疗后,中药组中医症候积分、癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原125(CA125)水平低于对照组,中药组KPS、QLQ-CR38评分高于对照组(均P<0.05)。与治疗前比较,两组治疗后血红蛋白、白细胞计数、中性粒细胞计数、血小板计数降低,但中药组各项指标高于对照组(均P<0.05)。中药组胃肠道反应和骨髓抑制发生率低于对照组(均P<0.05)。中药组疾病控制率高于对照组(P<0.05)。结论:参苓白术散加减辅助CRC化疗效果显著,可有效控制疾病进展,改善中医症候,调节肿瘤标志物水平与免疫功能,提高患者生活质量,且能减少化疗后胃肠道反应和骨髓抑制。
Abstract:
Objective:To investigate the effects of modified Shenling Baizhu powder on bone marrow suppression and immune function in patients with CRC after chemotherapy.Methods:A total of 61 patients with CRC undergoing chemotherapy were enrolled for prospective study, they were divided into control group and Chinese medicine group according to random number table method.31 patients in the control group were received XELOX,FOLFOX or SOX chemotherapy regimens.30 patients in the Chinese medicine group were treated with modified Shenling Baizhu powder on the basis of the control group,and both groups were treated for two consecutive cycles.The scores of TCM syndromes,tumor markers,blood routine,KPS and QLQ-CR38 score,adverse reactions and clinical curative effect were compared between the two groups.Results:After treatment,TCM syndrome score,the levels of CEA,CA199 and CA125 in TCM group were lower than those in control group,and the scores of KPS and QLQ-CR38 in TCM group were higher than those in control group(all P<0.05).Compared with before treatment,hemoglobin,white blood cell count,neutrophil count and platelet count were decreased in both groups after treatment,but the indexes in the Chinese medicine group were higher than those in the control group(all P<0.05).The incidence of gastrointestinal reaction and myelosuppression in Chinese medicine group was lower than that in control group(all P<0.05).The disease control rate of Chinese medicine group was higher than that of control group(P<0.05).Conclusion:The effect of modified Shenling Baizhu powder is significant in the treatment of CRC after chemotherapy,which can effectively control disease progression,improve TCM symptoms,regulate tumor markers and immune function,and thus improve quality of life,and reduce gastrointestinal reactions and bone marrow suppression after chemotherapy.

参考文献/References:

[1] Baidoun F,Elshiwy K,Elkeraie Y,et al.Colorectal cancer epidemiology:Recent trends and impact on outcomes[J].Curr Drug Targets,2021,22(9):998-1009.
[2] 刘思琦,张 申,凡会霞,等.中医治疗结直肠癌术后研究进展[J].光明中医,2023,38(1):183-186.
[3] Innamarato P,Pilon-Thomas S.Reactive myelopoiesis and the onset of myeloid-mediated immune suppression:Implications for adoptive cell therapy[J].Cell Immunol,2021,361(1):104277-104281.
[4] 冯燕茹,刘鲁迎,朱 远.中性粒细胞与白蛋白比值预测病理Ⅱ/Ⅲ期直肠癌术后辅助放化疗急性不良反应和生存[J].中华放射医学与防护杂志,2019,39(9):663-667.
[5] 王唯全,李 萍,王楚盈,等.结直肠癌的病因病机与药物治疗的研究进展[J].长春中医药大学学报,2020,36(1):194-197.
[6] 马永利,李镜辉,姚学清.参苓白术散辅助化疗治疗结直肠癌疗效和安全性的Meta分析[J].暨南大学学报:自然科学与医学版,2022,43(5):532-546.
[7] 葛均波,徐永健,王 辰.内科学[M].9版.北京:人民卫生出版社,2018:381-383.
[8] 中华中医药学会.中医内科常见病诊疗指南(西医疾病部分)[J].中国中医药现代远程教育,2011,9(18):151-153.
[9] 李 杰,林洪生.《中药新药治疗恶性肿瘤临床研究技术指导原则》修订过程及解析[J].中国新药杂志,2016,25(16):1833-1837.
[10] 吴 斌,武丽桂,袁 玲,等.肿瘤晚期患者生存期预测研究进展[J].中华护理杂志,2019,54(2):295-300.
[11] Ganesh V,Agarwal A,Popovic M,et al.Comparison of the FACT-C,EORTC QLQ-CR38,and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer:A literature review[J].Support Care Cancer,2016,24(8):3661-3668.
[12] Freites-Martinez A,Santana N,Arias-Santiago S,et al.Using the common terminology criteria for adverse events(CTCAE-Version 5.0)to evaluate the severity of adverse events of anticancer therapies[J].Actas Dermosifiliogr,2021,112(1):90-92.
[13] Lalchandani UR,Sahai V,Hersberger K,et al.A radiologist's guide to response evaluation criteria in solid tumors[J].Curr Probl Diagn Radiol,2019,48(6):576-585.
[14] 李 瑞,袁 宇,蔡 挺.结直肠癌发病机制及中西医治疗研究进展[J].世界科学技术-中医药现代化,2022,24(1):289-297.
[15] 李振前,杨梦春,刘戎惠,等.扶正消癌汤合四君子汤联合卡培他滨治疗晚期结直肠癌临床研究[J].陕西中医,2022,43(8):1037-1040.
[16] 谢燕东,张静瑜,樊晴伶,等.参苓白术散联合复方谷氨酰胺肠溶胶囊对肠易激综合征患者的肠黏膜屏障功能及5-HT、IFN-γ、IL-8水平的影响[J].现代生物医学进展,2019,19(22):4269-4272.
[17] 梁 想,王梅青.参苓白术散联合美沙拉嗪治疗溃疡性结肠炎疗效研究[J].陕西中医,2020,41(9):1251-1253.
[18] 杨朝美,冯 杰,郎 磊,等.CTC、CEA、CA125联合检测在结直肠癌中的临床价值[J].检验医学,2021,36(9):901-905.
[19] 王 蔚,王 旭,余苏云,等.人参皂苷Rg3调节免疫检查点PD-L1抑制肺癌Lewis细胞增殖的作用及机制研究[J].中草药,2019,50(1):166-171.
[20] 丁 欢,吴承杰,潘娅岚,等.黄芪及当归改善化疗后骨髓抑制的分子机制研究进展[J].中国医药导报,2020,17(5):23-26.

相似文献/References:

[1]吴昭利,李成军,李仁廷,等.通麻汤联合穴位注射治疗结直肠癌奥沙利铂化疗相关外周神经毒性疗效研究*[J].陕西中医,2019,(9):1247.
　WU Zhaoli,LI Chengjun,LI Renting,et al.Clinical study on Tongma decoction combined with acupoint injection in the treatment of peripheral neurotoxicity related to oxaliplatin chemotherapy for colorectal cancer[J].,2019,(8):1247.
[2]梁 想,王梅青△.参苓白术散联合美沙拉嗪治疗溃疡性结肠炎疗效研究[J].陕西中医,2020,(9):1251.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.021]
[3]王 渊,袁 捷△,韩祖成.韩祖成运用抑木扶土法治疗卒中后抑郁经验采撷*[J].陕西中医,2020,(12):1803.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.033]
[4]林增海,陆 军,王凯松.槲皮素对5-FU诱导的结直肠癌SW480细胞耐药及自噬调控机制研究[J].陕西中医,2021,(10):1338.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.004]
　LIN Zenghai,LU Jun,WANG Kaisong.Regulatory mechanism of quercetin on resistance and autophagy of 5-FU induced colorectal cancer SW480 cells[J].,2021,(8):1338.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.004]
[5]吴文玉,张玺金,王 凯,等.肺脾相关理论在肺系疾病中的运用[J].陕西中医,2023,(1):88.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.021]
　WU Wenyu,ZHANG Xijin,WANG Kai,et al.The application of pulmonary-spleen-related pathogenesis in lung diseases[J].,2023,(8):88.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.021]
[6]黄舒然,姚宏凤,丁海拔,等.参苓白术散联合沙美特罗氟替卡松治疗支气管哮喘慢性持续期疗效及对患者机体氧化-抗氧化平衡的影响[J].陕西中医,2023,(6):730.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.010]
　HUANG Shuran,YAO Hongfeng,DING Haiba,et al.Effect of Shenling Baizhu powder combined with salmeterol and fluticasone in the treatment of chronic bronchial asthma on the balance of body oxidation and antioxidation[J].,2023,(8):730.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.010]
[7]郑佳露,郑金洲,顾 贤.藤龙补中汤联合化疗治疗晚期结直肠癌疗效研究[J].陕西中医,2023,(8):1042.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.010]
　ZHENG Jialu,ZHENG Jinzhou,GU Xian.Observation on the therapeutic effect of Tenglong Buzhong decoction combined with chemotherapy on advanced colorectal cancer[J].,2023,(8):1042.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.010]
[8]刘云平,林才志,杨叶华,等.参苓白术散治疗功能性肠病伴腹泻研究进展[J].陕西中医,2023,(10):1494.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.037]
　LIU Yunping,LIN Caizhi,YANG Yehua,et al.Research progress on the treatment of functional bowel diseases with diarrhea by Shenling Baizhu San[J].,2023,(8):1494.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.037]
[9]张国星,李恩泽,温 泉,等.益气养荣汤对结直肠癌术后化疗患者骨髓抑制、Treg/Th17细胞、无进展生存期的影响[J].陕西中医,2024,(4):490.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.012]
[10]塔吉姑丽·吐逊,陈治宇,马琪琪,等.白头翁汤联合PD-1抑制剂对结肠癌小鼠免疫微环境的影响[J].陕西中医,2025,46(2):170.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.005]
　TAJIGULI Tuxun,CHEN Zhiyu,MA Qiqi,et al.Effect of Baitouweng decoction combined with PD-1 inhibitor on immune micro-environment of colon cancer mice[J].,2025,46(8):170.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.005]

备注/Memo

备注/Memo:
基金项目:安徽省卫生计生委中医药科研项目(2014ZY68)
更新日期/Last Update: 2023-08-10